Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

50 results about "Cyclophilin G" patented technology

Cyclosporin a conjugates and uses therefor

InactiveUS6316405B1Highly effective to treat or prevent neurological disordersAct synergisticallyNervous disorderMetabolism disorderAmyotrophic lateral sclerosisAmyloid
Disclosed are conjugates of Abeta-binding peptides and CsA analogs and conjugates of Abeta-binding peptides and FK506 Binding Peptide inhibitors. These conjugates chemically induce dimerization of either cyclophilin or FK506 Binding Peptide with Abeta peptide, a major component of amyloid plaques found in neurological disorders such as Alzheimer's disease, multiple sclerosis, and amyotrophic lateral sclerosis. The conjugates are useful in the treatment of neurological diseases involving the formation of amyloid plaques because they inhibit and / or prevent the aggregation and deposition of Abeta peptide into plaques.
Owner:WISCONSIN ALUMNI RES FOUND

Bisubstituted carbocyclic cyclophilin binding compounds and their use

The present invention relates to novel, non-peptidic small organic compounds having an affinity for cyclophilin (CyP)-type immunophilin proteins. In the compounds of this invention, at least two carbo- or heterocyclic groups are attached to a central saturated, partially saturated, or aromatic 5-6 membered carbocyclic ring by a combination of straight or branched linker chains. The invention further relates to pharmaceutical compositions comprising one or more of the said compounds, and to the uses of these compounds and compositions for binding CyP-type proteins, inhibiting their peptidyl-prolyl isomerase activity, and for research, development, and therapeutic applications in a variety of medical disorders, such as neurological disorders, hair loss disorders, ischemic disorders, and disorders caused by viral or protozoan infection.
Owner:GUILFORD PHARMACEUTICALS INC

TACI-immunoglobulin fusion proteins

Molecules that interfere with the binding of a tumor necrosis factor receptor with its ligand, such as a soluble receptor, have proven usefulness in both basic research and as therapeutics. The present invention provides improved soluble transmembrane activator and calcium modulator and cyclophilin ligand-interactor (TACI) receptors.
Owner:ZYMOGENETICS INC

Lentiviral protein delivery system for rna-guided genome editing

ActiveUS20180223313A1HydrolasesAntibody mimetics/scaffoldsÎ’ globin geneA-DNA
The invention is directed to a system comprising a lentivirus vector particle which encodes at least one guide RNA sequence that is complementary to a first DNA sequence in a host cell genome, a Cas9 protein, and optionally a donor nucleic acid molecule comprising a second DNA sequence. The invention also is directed to a method of altering a DNA sequence in a host cell using such a system, where the host cell can be in a human and the altered DNA can be of the human β-globin gene. The invention also is directed to a fusion protein comprising a Cas9 protein and a cyclophilin A (CypA) protein. The invention also is directed to sequences of vectors that can be used in the system and method.
Owner:UNITED STATES OF AMERICA

Cyclosporins to treat alzheimer's disease

Non-immunosuppressive, cyclophilin-binding cyclosporins, are useful as neuroprotective agents, e.g. in the prevention or treatment of pathological conditions associated with A beta secretion and / or production.
Owner:NOVARTIS AG

Ligand

The present invention provides a variant proliferation-inducing ligand (APRIL), which has a higher binding affinity to BCMA than wild-type APRIL; and / or altered binding kinetics compared with wild-type APRIL, and / or a higher BCMA:TACI (transmembrane activator and calcium modulator and cyclophilin ligand interactor) binding ratio than wild-type APRIL and which comprises mutations at one or more of the following positions: A125, V174, T175, M200, P201, S202, H203, D205 and R206.
Owner:UCL BUSINESS PLC

Methods and reagents for analyzing protein-protein interfaces

The present disclosure provides methods and reagents useful for analyzing protein-protein interfaces such as interfaces between a presenter protein (e.g., a member of the FKBP family, a member of the cyclophilin family, or PIN1) and a target protein. In some embodiments, the target and / or presenter proteins are intracellular proteins. In some embodiments, the target and / or presenter proteins are mammalian proteins.
Owner:REVOLUTION MEDICINES INC

Methods of treating a ras protein-related disease or disorder

Disclosed are RAS(ON) multi-selective inhibitor compositions and methods of treating RAS protein-related diseases or disorders using an intermittent dosing regimen. RAS(ON) multi-selective inhibitors having tight binding to cyclophilin A (CypA) result in high exposure levels, prolonged tissue retention, and / or slow clearance rates, thereby increasing the risk of inhibition of wild-type RAS in normal tissues. Accordingly, provided herein are methods for the safe and effective dosing of low KD1 RAS(ON) multi-selective inhibitors using an intermittent dosing regimen. Also provided are methods of selecting or identifying such RAS(ON) multi-selective inhibitors suitable for intermittent administration.
Owner:REVOLUTION MEDICINES INC

Therapeutic compositions and methods for managing treatment-related effects

Disclosed herein are methods and compositions for preventing or reducing adverse events associated with administration of a RAS(ON) inhibitors. Thus, disclosed are compositions and methods for treating or preventing RAS(ON) inhibitor therapy-associated rash or mucositis. The methods involve administering a compound that binds to cyclophilin A (CypA) to compete with a RAS(ON) inhibitor for CypA binding, thereby reducing tri-complex formation in non-tumor tissues. These approaches may improve the tolerability of RAS(ON) inhibitor therapies without compromising efficacy.
Owner:REVOLUTION MEDICINES INC

Use of modified cyclosporins for the treatment of HCV disorders

PendingUS7968518B2Eliminate infectionAlleviate or eliminate oneBiocideDigestive systemDiseaseCyclosporins
Disclosed are non-immunosuppressive cyclophilin-binding cyclosporins, e.g., of formula (I, Ia or II) as defined herein, having useful properties in the prevention of Hepatitis C infections.
Owner:NOVARTIS AG

Taci-immunoglobulin fusion proteins

InactiveCN101628111ANervous disorderAntipyreticCyclophilin GCalcium modulation
Molecules that interfere with the binding of a tumor necrosis factor receptor with its ligand, such as a soluble receptor, have proven usefulness in both basic research and as therapeutics. The present invention provides improved soluble transmembrane activator and calcium modulator and cyclophilin ligand-interactor (TACI) receptors.
Owner:ZYMOGENETICS INC

Chimeric antigen receptor

The present invention provides a cell comprising first and second chimeric antigen receptors (CARs), which bind to different antigens, wherein the first CAR binds to Transmembrane activator and calcium modulator and cyclophilin ligand (CAML) interactor (TACI). The present invention also provides a cell comprising a tanCAR comprising first and second antigen-binding domains which bind to differentantigens, wherein the first antigen binding domain binds the antigen Transmembrane activator and calcium modulator and cyclophilin ligand (CAML) interactor (TACI). The present invention further provides corresponding nucleic acid sequences and / or constructs, kits and vectors comprising said nucleic acid sequences and / or constructs, molecules and methods for making such cells. The cells may be used in cellular immunotherapy approaches for treating diseases such as multiple myeloma.
Owner:AUTOLUS LIMIED

Phalaenopsis spp. cyclophilin CYP gene and applications thereof

The invention belongs to the technical field of Phalaenopsis spp. genetic engineering, and particularly relates to a Phalaenopsis spp. cyclophilin CYP gene and patent application affairs thereof. ThecDNA sequence of the gene is 901 bp in length, and the 277th to 728th bases are a conserved sequence thereof. The cyclophilin CYP encoded by the gene includes 173 amino acids. The Phalaenopsis spp. cyclophilin gene CYP is cloned and analyzed for the first time in the invention. By utilization of real-time fluorescent quantitative PCR technology, preliminary studies show that this gene can be stably expressed in different periods of growth and development and different tissues of the Phalaenopsis spp., and therefore the gene is suitable for application as a reference gene in expression analysisof related genes in the Phalaenopsis spp.. In general, the variety of reference genes in expression research of related genes of Phalaenopsis spp. is enriched, and a good foundation is laid for accurate analysis of gene expression detection, so that the gene has good application value.
Owner:ZHENGZHOU NORMAL UNIV

Brain-targeted cyclosporine A nano-drug as well as preparation method and application thereof

The invention relates to the technical field of biological targeted delivery systems, and discloses a brain-targeted cyclosporine A nano-drug as well as a preparation method and application thereof. The brain-targeted cyclosporine A nano-drug comprises a fusion membrane which is a composite membrane, the composite membrane comprises a mitochondrial membrane and a cell membrane or an organelle membrane fused with the mitochondrial membrane, and specifically, the composite membrane can be at least one of a platelet membrane, a macrophage membrane, a neutrophile granulocyte membrane and an erythrocyte membrane; the embedded molecule is modified on the fusion membrane; the embedded molecule is a functional molecule crossing a blood brain barrier; the inner cavity substance is a cyclosporine A liposome; and the inner cavity object is wrapped by the fusion film. The platelet membrane in the nano-drug provided by the invention can drive RMP-LipCsA to be homed and combined with brain microvascular endothelial cells, then the RVG29 is used for mediating blood brain barrier penetration, and then CsA is further collected from an injured part and accurately transferred to the injured brain cells; and then the mitochondrial membrane is accurately targeted to endogenous mitochondria of cells through the mitochondrial targeting function of the mitochondrial membrane, and is combined with cyclophilin A in the mitochondria, so that the mitochondrial function is improved, and the neuroprotective effect is achieved.
Owner:CHONGQING QUANSHENG PHARM TECH CO LTD +1

Composition and method for facilitating the internalization of a therapeutic agent into a cell

The present invention is a composition and method for facilitating the internalization of a therapeutic agent into a cell. Specifically, the invention relates to the use of the extracellular domain of basigin-2, cyclophilin, or anti-basigin-2 antibody or antibody fragment as a delivery moiety for internalization of a therape.
Owner:THE BOARD OF TRUSTEES OF THE UNIV OF ILLINOIS

Compounds that participate in cooperative binding and uses thereof

The invention features compounds (e.g., macrocyclic compounds) capable of modulating biological processes, for example through binding to a presenter protein (e.g., a member of the FKBP family, a member of the cyclophilin family, or PIN1) and a target protein (e.g., a eukaryotic target protein such as a mammalian target protein or a fungal target protein or a prokaryotic target protein such as a bacterial target protein). These compounds bind endogenous intracellular presenter proteins, such as the FKBPs or cyclophilins, and the resulting binary complexes selectively bind and modulate the activity of intracellular target proteins. Formation of a tripartite complex among the presenter protein, the compound, and the target protein is driven by both protein-compound and protein-protein interactions, and both are required for modulation of the targeted protein's activity.
Owner:REVOLUTION MEDICINES INC

Composition for preventing hair loss or enhancing hair growth comprising cyclophilin a

ActiveUS20150209262A1Inhibit IL- expressionModulate activityCosmetic preparationsCompound screeningNucleotideSkin cell
The present invention relates to a composition for preventing hair loss or enhancing hair growth which comprises a cyclophilin A (CypA) protein, a nucleic acid having a nucleotide sequence encoding the CypA protein, or a CypA protein expression recombinant vector. The composition of the present invention is administered into skin cells to inhibit the IL-1 expression of the skin cells, to modulate the activities of ERK and c-jun, and to increase the expression of NF-kB p65, thereby promoting the growth and development of hair follicles. Therefore, the composition of the present invention can be useful in preventing hair loss or enhancing hair growth.
Owner:UNIV IND COOP GRP OF KYUNG HEE UNIV

Cyclophilin 40 for reduction of neurotoxic fibrils and treatment of neurodegenerative diseases

The present invention concerns the use of peptidyl-prolyl isomerase cyclophilin 40 (CyP40) for reduction of neurotoxic fibrils and treatment and prevention of neurodegenerative diseases associated with amyloid fibril aggregation. Aspects of the invention include compositions, methods, dosage forms, and kits for treating or preventing a neurodegenerative disease or condition associated with amyloid fibril aggregation in a human or animal subject, and for disaggregating neurofibrillary aggregates in vitro or in vivo, using CyP40, or a biologically active fragment thereof.
Owner:UNIV OF SOUTH FLORIDA

Cyclophilin inhibitors and uses thereof

The present disclosure provides compounds defined by Formulae 1-6 and their use as cyclophilin inhibitors for the prevention or treatment of a disease or disorder, such as a cyclophilin-mediated disease or disorder, in particular a cyclophilin A-mediated disease or disorder.
Owner:FARSIGHT MEDICAL TECH (SHANGHAI) CO LTD

Vaccine Used For Preventing Toxoplasma Gondii Infection And Preparation Method Therefor

Provided is a protein having Toxoplasma immunogenicity, the protein being a cyclophilin mutant protein and consisting of the amino acid sequence as shown in SED 2. Further provided is a nucleic acid that may encode a protein having Toxoplasma immunogenicity, which has the nucleic acid sequence as shown in SEQ ID NO. 1. Further provided is a vaccine, which is obtained by double-digesting a Toxoplasma antigen gene and then linking the same to a prokaryotic expression vector such as pET28a, and transforming the same into a prokaryotic expression engineering strain such as BL21(DE3), thereby inducing the high-efficiency expression thereof, wherein the inducing the high-efficiency expression thereof, wherein the purified protein is a soluble protein which maintains specific immunogenicity thereof.
Owner:HAIMU ANIMAL HEALTH PROD (SHANDONG) CO LTD

Methods of treating a ras protein-related disease or disorder

Disclosed are RAS(ON) multi-selective inhibitor compositions and methods of treating RAS protein-related diseases or disorders using an intermittent dosing regimen. RAS(ON) multi-selective inhibitors having tight binding to cyclophilin A (CypA) result in high exposure levels, prolonged tissue retention, and / or slow clearance rates, thereby increasing the risk of inhibition of wild-type RAS in normal tissues. Accordingly, provided herein are methods for the safe and effective dosing of low KD1 RAS(ON) multi-selective inhibitors using an intermittent dosing regimen. Also provided are methods of selecting or identifying such RAS(ON) multi-selective inhibitors suitable for intermittent administration.
Owner:REVOLUTION MEDICINES INC

Antigen binding proteins specific for transmembrane activators and CAML interactors (TACI)

Provided herein are antigen binding proteins that specifically bind to and / or detect transmembrane activators and calcium modulators and cyclophilin ligand (CAML) interactors (TACI) / TNFRSF13B, where the antigen binding proteins comprise a CDR sequence having GFSITSDYA (SEQ ID NO: 1) in relation to CDRH1, ISSYSGST (SEQ ID NO: 2) in relation to CDRH2, ARVVSTSFDS (SEQ ID NO: 3) in relation to CDRH3, ESVDNYGISF (SEQ ID NO: 4) in relation to CDRL1, VAS (SEQ ID NO: 5) in relation to CDRL2, and QQSKEVPYT (SEQ ID NO: 6) in relation to CDRL3, or has an amino acid sequence at least 85% identical to the sequence, or has one or two amino acid sequences different from the sequence. Also provided herein are polynucleotides, vectors, and host cells of the antigen binding proteins. Further provided herein are pharmaceutical compositions and methods of treating a disease, such as TACI-positive multiple myeloma.
Owner:AGENCY FOR SCI TECH & RES

Protac compound with cyclophilin a degradation activity, preparation method therefor, and use thereof

Disclosed are a PROTAC compound with cyclophilin A degradation activity, a preparation method therefor, and use thereof. The structural formula of the PROTAC compound is represented by Formula (I). The compound represented by Formula (I) provided by the present invention can be used for preventing and / or treating CypA-mediated diseases, such as CypA-mediated inflammation, autoimmune diseases, and / or tumors. The present invention also provides a pharmaceutical composition comprising the compound represented by Formula I as an active ingredient and at least one pharmaceutically acceptable carrier, excipient, and / or diluent. The PROTAC compound provided by the present invention can degrade CypA protein in a targeted manner, so that the PROTAC compound can be used for preparing medicaments for treating inflammation, autoimmune diseases, tumors, and other related diseases. The compound represented by Formula I in the present invention has a significant inhibitory function on virus-induced pneumonia, rheumatoid arthritis, and lung cancer cell migration and infiltration.
Owner:SHENZHEN BAY LAB

Cyclosporin a-binding protein

Disclosed are: a composition and a method for the diagnosis and / or the treatment of a CSABP-related disease, the regulation of the proliferation of an RNA virus and the regulation of an RNA-metabolizing system, which targets a cyclosporin A-binding protein (CSABP); a method for the screening of a component that targets a CSABP; a composition and a method for the detection / inhibition of CsA, NS5B or cyclosphilin B by utilizing a CSABP; a promoter for a CSABP; a method for the screening of a substance capable of regulating the expression of a CSABP by utilizing the promoter; and a method for the determination of the occurrence or clinical stage of a CSABP-related disease.
Owner:TOKYO UNIVERSITY OF SCIENCE +3

Extracellular cyclophilin inhibitor and use thereof

The present invention belongs to the technical field of biomedicine, and specifically relates to an extracellular cyclophilin inhibitor and the use thereof, wherein the structural general formula of the extracellular cyclophilin inhibitor of the present invention is as shown in formula (I). According to the present invention, a group capable of reacting with sulfhydryl of cysteine at a specific site on blood albumin is extracted by means of a side chain of a new cyclosporin derivative, and a drug conjugate is rapidly formed after same enters the body, which can effectively restrict the drug to the extracellular area and form targeted inhibition of extracellular cyclophilin, thereby achieving the aim of treating diseases associated therewith.
Owner:PEKING UNIV SHENZHEN GRADUATE SCHOOL